Leadership Change at Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. (NASDAQ: TERN), a clinical-stage biopharmaceutical company focused on developing small-molecule candidates for serious diseases, has announced a significant leadership addition. The Company has appointed Andrew Gengos as its new Chief Financial Officer, effective immediately. This exciting move comes at a pivotal time as Terns continues to innovate in areas such as oncology and obesity treatment.
Andrew Gengos: A Valuable Addition
In welcoming Gengos to the team, Amy Burroughs, the Chief Executive Officer of Terns Pharmaceuticals, expressed her enthusiasm. Burroughs believes that Andrew's vast experience and strong leadership skills will play a critical role in furthering Terns' mission to create impactful medicines that enhance patient lives. With Gengos onboard, the Company anticipates positive changes in its financial strategy that could propel its ambitious projects.
Comments from the New CFO
Mr. Gengos shared his excitement about joining Terns, highlighting the Company's leading programs in oncology and obesity. He expressed his eagerness to collaborate with the existing leadership to strengthen Terns' financial foundation and expand its capacity to deliver innovative treatments. Gengos brought to the table over 25 years of extensive finance and corporate strategy experience in the life sciences and biotechnology sectors, an asset that will be invaluable as Terns pushes forward with its initiatives.
A Look at Gengos' Background
Before joining Terns, Andrew Gengos served as CFO at Athira Pharma, where he successfully navigated the financial landscape of the company. His track record includes serving as Chief Business Officer at Cyteir Therapeutics, successfully leading that entity to its public offering. Notably, Gengos has also held senior executive roles, including CEO positions at ImmunoCellular Therapeutics and Neuraltus Pharmaceuticals, leading strategic initiatives across diverse therapeutic areas.
About Terns Pharmaceuticals
Terns Pharmaceuticals is dedicated to creating therapies that address significant health challenges. Its pipeline encompasses multiple clinical-stage programs, each designed to tackle diseases such as oncology and obesity. Among these programs is an allosteric BCR-ABL inhibitor and a small-molecule GLP-1 receptor agonist, showcasing the Company’s commitment to innovation. With Gengos at the helm of its financial strategy, Terns includes a focus on continued development efforts, including a GIPR antagonist nominee aimed at transforming patient care.
Looking Ahead
Terns Pharmaceuticals stands at a promising juncture, with Andrew Gengos’ expertise expected to enhance its operational strategies and financial stability. The Company is well-positioned to make significant strides in the development of crucial therapies geared toward serious conditions. As they work together towards remarkable achievements in the future, stakeholders can anticipate continued updates on their clinical programs and corporate strategies.
Frequently Asked Questions
Who is Andrew Gengos?
Andrew Gengos is the newly appointed Chief Financial Officer of Terns Pharmaceuticals, bringing over 25 years of experience in finance and corporate strategy in the biotechnology sector.
What is Terns Pharmaceuticals' focus?
Terns Pharmaceuticals focuses on developing small-molecule therapies for serious diseases, specifically in the areas of oncology and obesity.
Why is the appointment of Andrew Gengos significant?
The appointment of Andrew Gengos is significant because his extensive experience in finance and corporate strategy positions him to help propel Terns Pharmaceuticals' growth and innovation.
What are the key programs at Terns Pharmaceuticals?
Terns' key programs include an allosteric BCR-ABL inhibitor and a small-molecule GLP-1 receptor agonist, among others, that target critical health issues.
How can I learn more about Terns Pharmaceuticals?
For more information about Terns Pharmaceuticals and its pipeline, visit their website at www.ternspharma.com.
